Group 1 - McEwen Mining (MUX) shares have increased by 18.3% over the past four weeks, closing at $11.5, with a mean price target of $14.99 indicating a potential upside of 30.4% [1] - The average price targets range from a low of $13.75 to a high of $15.70, with a standard deviation of $0.88, suggesting a relatively high agreement among analysts [2] - Analysts are optimistic about MUX's earnings prospects, as indicated by a significant increase in earnings estimate revisions, which correlates with potential stock price movements [4][11] Group 2 - Over the last 30 days, the Zacks Consensus Estimate for MUX's current year earnings has increased by 94.6%, with no negative revisions [12] - MUX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [14]

Core Viewpoint - Mineralys Therapeutics, Inc. (MLYS) shows significant upside potential with a mean price target of $36.25, indicating a 154.2% increase from the current price of $14.26 [1][2]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $11.25, suggesting variability in analyst predictions. The lowest estimate is $15.00 (5.2% increase), while the highest is $48.00 (236.6% increase) [2]. - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about MLYS's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 1.6%, with one estimate moving higher and no negative revisions [12]. Zacks Rank and Investment Potential - MLYS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13]. - While the consensus price target may not be a reliable indicator of the extent of gains, it does provide a directional guide for potential price movement [14].

Core Viewpoint - The average brokerage recommendation (ABR) for Diebold Nixdorf, Incorporated (DBD) is 1.00, indicating a Strong Buy based on recommendations from three brokerage firms, all of which are Strong Buy [2][5] Brokerage Recommendation Trends - The current ABR of 1.00 is derived from three Strong Buy recommendations, representing 100% of all recommendations [2] - Despite the Strong Buy recommendation, reliance solely on brokerage recommendations may not be wise, as studies show limited success in guiding investors to stocks with the best price increase potential [5][10] Zacks Rank and Its Importance - Zacks Rank categorizes stocks into five groups, from Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell), and is based on earnings estimate revisions, which correlate strongly with near-term stock price movements [8][11] - The Zacks Rank is distinct from ABR, as it is a quantitative model that reflects timely earnings estimate revisions, while ABR may not be up-to-date [9][13] Current Earnings Estimates for DBD - The Zacks Consensus Estimate for Diebold Nixdorf, Incorporated remains unchanged at $3.57 for the current year, indicating steady analyst views on the company's earnings prospects [14] - The unchanged consensus estimate has resulted in a Zacks Rank 3 (Hold) for Diebold Nixdorf, suggesting caution despite the Buy-equivalent ABR [15]

Group 1 - Alvotech (ALVO) shares have increased by 0.3% over the past four weeks, closing at $9.16, with a mean price target of $17.5 indicating a potential upside of 91.1% [1] - The mean estimate consists of four short-term price targets with a standard deviation of $7, where the lowest estimate is $14.00 (52.8% increase) and the highest is $28.00 (205.7% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has risen by 6.3% over the last 30 days, with one estimate moving higher and no negative revisions [12] - Alvotech holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement [14]

Group 1 - Apogee Enterprises (APOG) closed at $43.05, with a 10.6% gain over the past four weeks, and a mean price target of $54 indicates a 25.4% upside potential [1] - The average price targets range from a low of $45.00 to a high of $63.00, with a standard deviation of $9, suggesting a variability in estimates [2] - Analysts have shown increasing optimism about APOG's earnings prospects, with a 2.9% increase in the Zacks Consensus Estimate for the current year [11][12] Group 2 - The Zacks Rank for APOG is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts regarding the stock's price movement [9] - The positive trend in earnings estimate revisions has a strong correlation with near-term stock price movements, indicating potential upside [11]

Core Viewpoint - Crescent Energy (CRGY) has seen a 3.7% increase in share price over the past four weeks, closing at $8.92, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $14.92, representing a 67.3% upside [1] Price Targets - The average of 12 short-term price targets ranges from a low of $10.00 to a high of $20.00, with a standard deviation of $2.75, indicating variability among estimates [2] - The lowest estimate suggests a 12.1% increase from the current price, while the highest estimate indicates a 124.2% upside [2] Analyst Consensus - There is strong agreement among analysts regarding CRGY's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - The Zacks Consensus Estimate for the current year has increased by 13.5% over the past month, with three estimates rising and one falling [12] Zacks Rank - CRGY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [13] Caution on Price Targets - While price targets are a common metric for investors, relying solely on them for investment decisions may not be wise due to historical inaccuracies in predicting stock price movements [3][7][10]

Core Viewpoint - On Holding (ONON) shares have shown a slight increase of 0.3% over the past four weeks, closing at $51.64, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $64.64, representing a 25.2% upside [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of 22 short-term price targets with a standard deviation of $6.45, indicating variability among analysts; the lowest estimate is $50.00 (3.2% decline), while the highest is $75.00 (45.2% increase) [2][9]. - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9][10]. Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about ONON's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11][12]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 1.6%, with two estimates moving higher and one lower [12]. - ONON holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [13]. Conclusion on Price Movement - While the consensus price target may not be a reliable predictor of the extent of ONON's gains, the implied direction of price movement appears to be a useful guide for investors [14].

Core Viewpoint - Commvault Systems (CVLT) has experienced a decline of 5.1% in its stock price over the past two weeks, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging to counteract selling pressure [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out of the stock, with reduced selling pressure and a potential shift in control from bears to bulls [2][5]. - This pattern is characterized by a small candle body with a long lower wick, suggesting that after reaching a new low, the stock found support and closed near its opening price [4][5]. - Hammer candles can appear on various timeframes and are utilized by both short-term and long-term investors [5]. Fundamental Analysis - Recent upward revisions in earnings estimates for Commvault are viewed as a bullish indicator, correlating strongly with potential near-term stock price movements [7]. - Over the last 30 days, the consensus EPS estimate for the current year has increased by 0.6%, indicating that analysts expect better earnings than previously predicted [8]. - Commvault currently holds a Zacks Rank of 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about Sterling Infrastructure (STRL) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Sterling Infrastructure cur ...

Core Viewpoint - Helios Technologies (HLIO) is positioned as a strong investment opportunity due to significant upward revisions in earnings estimates, indicating a positive earnings outlook and potential for continued stock price appreciation [1][2]. Earnings Estimate Revisions - The trend of increasing earnings estimate revisions reflects growing analyst optimism regarding Helios Technologies' earnings prospects, which is expected to positively influence its stock price [2]. - For the current quarter, Helios Technologies is projected to earn $0.49 per share, representing a year-over-year decline of 23.4%. However, the Zacks Consensus Estimate has increased by 6.38% due to one upward revision and no negative revisions in the last 30 days [6]. - For the full year, the earnings estimate stands at $1.90 per share, reflecting a 9.5% decrease from the previous year. Similar to the current quarter, the consensus estimate has risen by 6.15% following one upward revision and no negative revisions [7][8]. Zacks Rank and Performance - Helios Technologies currently holds a Zacks Rank 1 (Strong Buy), which is based on the positive estimate revisions and has historically shown strong performance, with Zacks 1 Ranked stocks averaging a 25% annual return since 2008 [3][9]. - The Zacks Rank system is designed to leverage earnings estimate revisions to guide investment decisions, with stocks rated Zacks Rank 1 and 2 significantly outperforming the S&P 500 [9]. Stock Performance - The stock of Helios Technologies has appreciated by 14.7% over the past four weeks, driven by favorable estimate revisions and positive earnings growth prospects, suggesting it may be a timely addition to investment portfolios [10].